Lunai Bioworks, Inc. received notification from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The company satisfied the terms of previous decisions and extension letters issued on April 2, 2026, and May 12, 2026. Consequently, the company will be subject to a mandatory one-year Panel monitor. If the company falls out of compliance with the Bid Price Rule during this monitoring period, it will be ineligible for standard compliance plans or extensions, potentially leading to a delisting determination. Lunai Bioworks, Inc. is a biotechnology company.